Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?
Open accessThe DOI matches its Crossref record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. The optimal therapeutic dose of sirolimus is not yet defined. Here, we report the history of a previously unknown ADPKD deceased donor whose kidneys were engrafted in two different recipients. One of the two received an immunosuppressive regimen based on sirolimus for 5 years while the other did not. After transplantation, both patients developed severe transplant cystic disease. Donor DNA sequence identified a new hypomorphic mutation in PKD1. The rate of cyst growth was identical in the two patients regardless of the treatment. While sirolimus treatment reduced the activation of mTOR in peripheral blood mononuclear cells, it failed to prevent mTOR activation in kidney tubular cells, this could account for the inefficiency of treatment on cyst growth. Together, our results suggest that the dose of sirolimus required to inhibit mTOR varies according to the tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Autosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Self-citationGenetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease
Harris, P. C., & Torres, V. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72272 · Cited by 338
Self-citationPyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways
Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., & Zhou, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr338 · Cited by 143
“Consistent with these findings in mice, a recent human study has demonstrated that two renal allograft recipient patients developed polycystic kidney disease in the donor kidney a few months after kidney transplantation, although the donor patient carried a PKD1 mutation and did not have cysts for 30 years (28).”
Result
Metadata
- Authors
- Canaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. ‐., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., & Legendre, C.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 10
- Issue
- 7
- Pages
- 1710-1715
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1550480781
- Cited by
- 69
- References
- 0
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level? https://app.cochat.ai/papers/10.1111/j.1600-6143.2010.03152.x
- The paper
- Canaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. ‐., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., & Legendre, C. (2010). Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level? American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2010.03152.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.